PhewyPompipi personal page - To The Moon

PhewyPompipi

PhewyPompipi

No personal profile

15Follow

14Followers

0Topic

0Badge

2022-12-30

$BioNTech SE(BNTX)$ what's going on?

2022-04-09

There is hope!

BioNTech: Buy The Dip

2022-04-05

$BioNTech SE(BNTX)$⛽⛽jiayou! Soar more please! 💪💪💪

2022-02-24

Still holding on, com'on!!!

BioNTech a buy at Wainwright, but price target lowered on long-term vaccine sales

2022-02-08

Why?????

Vaccine Stocks Slipped in Morning Trading

2022-01-24

$BioNTech SE(BNTX)$Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵

2022-01-18

Guess really need to hang on for a while more to see where this is going

BioNTech shares tumbled nearly 8% in morning trading

2022-01-11

$BioNTech SE(BNTX)$Pfizer CEO says Omicron-targeted vaccine is most likely outcome http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&utm_medium=social-media&utm_campaign=native-share

2022-01-06

Precisely...why are investors selling now, pushing the price to an all time low...

Vaccine Stocks Slid in Morning Trading

2022-01-06

$BioNTech SE(BNTX)$Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭

2021-09-22

Happy!

Apple sees 5M iPhone 13 pre-orders in China--report

2021-09-20

$Apple(AAPL)$Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?

2021-09-01

Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...

@Kel1:$BioNTech SE(BNTX)$Will this recover?

2021-08-30

$Apple(AAPL)$Could it go up to $159?/$160 mark? ?

2021-08-23

Hopefully it will rise to about its pre-glory price of $480+?

Sorry, the original content has been removed

2021-08-17

$Apple(AAPL)$will it go to $160? To hold or sell?

2021-08-16

$BioNTech SE(BNTX)$what is happening? Why was it doing well last week and today opening mkt and it sink so bad?

2021-08-13

Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?

BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity

2021-08-12

Fantastic positive news! Keeping fingers crossed!

BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster

2021-08-05

Sold it a day ago at a loss. Cut losses fast and place my bets elsewhere.

Lemonade drops over 12% in morning trading

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4087475573507020","uuid":"4087475573507020","gmtCreate":1624372765357,"gmtModify":1624500741691,"name":"PhewyPompipi","pinyin":"phewypompipi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":15,"tweetSize":50,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9927100586,"gmtCreate":1672411752745,"gmtModify":1676538687577,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$ &nbsp;</a>what's going on?","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$ &nbsp;</a>what's going on?","text":"$BioNTech SE(BNTX)$ what's going on?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9927100586","isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9015842718,"gmtCreate":1649467104525,"gmtModify":1676534516628,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"There is hope!","listText":"There is hope!","text":"There is hope!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015842718","repostId":"2225289895","repostType":2,"repost":{"id":"2225289895","kind":"news","pubTimestamp":1649412619,"share":"https://ttm.financial/m/news/2225289895?lang=&edition=fundamental","pubTime":"2022-04-08 18:10","market":"us","language":"en","title":"BioNTech: Buy The Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2225289895","media":"seekingalpha","summary":"U. J. Alexander/iStock Editorial via Getty Images BioNTech SE (NASDAQ:BNTX) is worth a lot more than","content":"<html><body><p><figure><picture> <img height=\"1024px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w240 240w\" width=\"1536px\"/> </picture><figcaption> <p>U. J. Alexander/iStock Editorial via Getty Images</p></figcaption></figure></p> <p><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (<span>NASDAQ:BNTX</span>) is worth a lot more than its current price. A year ago, BNTX's stock price was around $110. BNTX's stock price jumped from $113 on 7 April 2021 to $447 on 9 August 2021. Since<span> then, the stock’s price dropped 63%, even as the company reported strong 3Q 2021 and 4Q 2021 financial results. I estimate the stock is worth $264, implying a 56% upside potential. According to Seeking Alpha </span>ratings<span> (Wall Street price target), BNTX has a low price target of $164, a median price target of $251, and a high price target of $396. Also, according to Seeking Alpha quant rating, the stock is a Strong Buy.</span></p> <h2>4Q 2021 results</h2> <p>In its 4Q 2021 financial result, BioNTech reported total revenue of €5.5b, compared with 4Q 2020 total revenue of €345m, up 1500%. The company’s FY 2021 revenue grew more than 3800% YoY. BNTX reported a profit of €12.18 per diluted share in the fourth quarter of 2021, compared with a 4Q 2020 profit of €1.43 per diluted share. BioNTech’s net profit jumped from €15.2m in 2020 to €10.3b in 2021. In 2021, about 2.6 billion doses of Pfizer/BioNTech COVID-19 vaccine delivered to more than 165 countries. BioNTech increased its research and development expenses from €645m in 2020 to €949m in 2021, up 47%. BNTX's loans and borrowings jumped to more than €129m in 2021, up 1430% YoY. The company's total current liabilities increased from €606m in 2020 to €3482m in 2021. Moreover, on 31 March 2021, BioNTech announced entering into a share repurchase program, worth $1.5b over the next two years.</p> <h2>Estimation of BNTX’s 2022 vaccine delivery and 1Q 2022 revenue</h2> <p>In 2021, around 9 billion COVID-19 vaccine doses administered globally. Also, in 2021, 2.6 billion Pfizer/BioNTech vaccine doses delivered to more than 165 countries. Accounting for the time lag between providing and administering the vaccine doses, I estimate a 25% market share for Pfizer/BioNTech COVID-19 vaccine. BioNTech and Pfizer signed orders to manufacture 2.4 billion COVID-19 vaccine doses in 2022. I estimate there will be more orders in the next nine months.</p> <p>As of 6 April 2022, 4.98 billion people have received the COVID-19 vaccine worldwide (Table 1). According to the Bloomberg vaccine tracker, at the current pace of vaccination, “it will take another nine months until 75% of the population has received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose.” I estimate 2.657 billion doses of BNT162b2 will be delivered by the end of 2022. I should notice that my estimation is based on the assumption that 50% of the world population will receive the third dose of the COVID-19 vaccine, and 10% will receive the fourth dose of the COVID-19 vaccine by the end of 2022. On 29 March 2022, BioNTech reported that FDA authorized the second booster dose of the COVID-19 vaccine in individuals aged 50 years and older. In a few months, there might be authorization for the second booster dose in individuals aged below 50.</p> <p>Table 1 – Estimation of Pfizer/BioNTech vaccine delivery in 2022</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId8.png\"/> </picture><figcaption><p><span>Author's calculations</span></p></figcaption></figure></p> <p>In its fourth-quarter and full-year 2021 financial result and corporate update, BioNTech reiterated BioNTech COVID-19 vaccine revenue guidance of €13 billion to €17 billion. I estimate that if the world increases the pace of administering the first and second boosters of the COVID-19 vaccine in the next nine months, BioNTech’s full-year 2022 vaccine revenue may reach €19 billion. Also, based on quarterly results, I estimate a 1Q 2022 revenue of €5.3 billion for BioNTech (Table 2).</p> <p>Table 2 - 1Q 2022 revenue estimation</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId9.png\"/> </picture><figcaption><p><span>Author's calculations based on BioNTech's quarterly financial reports</span></p></figcaption></figure></p> <p>Figure 1 shows that in European Union and the United States, Pfizer/BioNTech vaccine is the most administered vaccine. According to ourworldindata.org, as of 28 March 2022, 77% of Pfizer/BioNTech vaccine administration globally belongs to the European Union and the United States. Also, respectively, 59% and 72% of vaccines administered in the United States and the European Union are manufactured by Pfizer/BioNTech. Furthermore, respectively, 61% (74 million doses) and 95% (87 million doses) of vaccine doses administered in South Korea and Japan were manufactured by Pfizer/BioNTech.</p> <p>Figure 1 - COVID-19 vaccine doses administered by manufacturer, European Union and United States</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId11.png\"/> </picture><figcaption><p><span>ourworldindata.org</span></p></figcaption></figure></p> <h2>Performance</h2> <p>From now, the numbers are in US$ as I use Seeking Alpha’s data in the performance section and valuation section.</p> <p>In the following section, I provided a detailed analysis of BioNTech’s capital structure for those readers who wish to scratch beneath the surface. In 2021, BNTX saw a very impressive 97% higher cash which was $2392.7m, versus the previous result of $1210.2m in 2020. The company’s debt increased in 2021 and sat at $286.7m, which is about 19% higher than its level of $240.2m at the end of 2020. Also, it is worth mentioning that BNTX’s equity surged amazingly during 2021 and sat at $8711.5m versus its level of $1371.8m at the end of 2020 (see Table 3).</p> <p>Table 3 – BioNTech’s capital structure</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId12.png\"/> </picture><figcaption><p><span>Author</span></p></figcaption></figure></p> <p>Analyzing BioNTech’s R&amp;D to revenue during the recent years and comparing it with its peers, we observe that BNTX had the least amount among its competitors. This ratio measures the amount of revenue that is related to research and development expenditures (see Table 4). In a word, the current strong financial conditions and low leverage ratios will likely bring considerable improvements during 2022.</p> <p>Table 4 – BioNTech’s R&amp;D/revenue ratio vs. its peers.</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId14.png\"/> </picture><figcaption><p><span>Author</span></p></figcaption></figure></p> <h2>Valuation</h2> <p>Using Comparable Company Analysis (CCA), I evaluated that BioNTech stock is attractive and undervalued. Comparing BioNTech SE with other peer competitors – Gilead Sciences (GILD), Moderna (MRNA), Biogen Inc. (BIIB) - and using the CCA method, I estimate that the stock's fair value is $265. This method reflects the real-market data and is an appropriate way of analyzing BioNTech due to the company’s stability. In the case of choosing competitors, I considered biotechnology companies with similar research and development fields, size, and profitability. Data was gathered from the most recent quarterly and TTM data.</p> <p>Analyzing other companies' ratios and comparing them with BNTX's, we can figure out that BioNTech looks relatively attractive and it is undervalued. The company's P/E ratio is 3.95x, which is far lower than the peer’s average of 6.95x. A stock with a lower P/E ratio is a value stock because it indicates that investors are paying less for every dollar of earnings they receive. Furthermore, the company’s EV/EBITDA is 3.73x compared with the peer’s average of 6.34x. In a word, the lower the EV/EBITDA, the cheaper the price for a company (see Figure 2).</p> <p>Figure 2 – BioNTech’s financial ratios vs. its peers</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId15.png\"/> </picture><figcaption><p><span>Author</span></p></figcaption></figure></p> <p>Besides BioNTech, I have done some analysis on the peer companies. Moderna's EV/EBIT amount is 3.44x, which is far lower than the peer's average. Also, Biogen’s EV/EBITDA is 8.61x, which is 34% higher than the group's average of 6.38x. Generally speaking, the higher EV/EBITDA implies that Biogen is potentially overvalued. Despite observing drops in BNTX's per-share price recently, using the CCA method, I evaluate that BNTX stock is potentially undervalued and has a considerable upside potential - a fair value of $265 (see Table 5).</p> <p>Table 5 – BNTX stock valuation based on CCA method</p> <p><figure><span><img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/7/55366256-16493572601020591.png\"/></span><figcaption><p><span>Author's calculations</span></p></figcaption></figure></p> <h2>Risks</h2> <p>BioNTech benefited from the pandemic in 2021. However, from now on, everything depends on the third dose and fourth dose of the COVID-19 vaccine. The company expects to release the data for the third dose regimen in children aged 6 months to 5 years in a few weeks. Also, BioNTech has not released the data for the fourth dose of the COVID-19 vaccine in adults aged 16 to 65 years. The time of data release for the third dose in children aged 5 years to 12 years is not determined yet. Also, BioNTech is working on the next generation of COVID-19 vaccines. It expects to release the data for the Omicron-based vaccine in a few weeks. In the second half of 2022, the company will release multiple updates on variant combinations and bivalent vaccines. There will be updates on the Influenza mRNA vaccine, infectious diseases vaccines, and oncology programs in the second half of 2022. Thus, as much as progress in any of the mentioned fields could help the company, bad news may cause the stock price to drop. Make sure you follow the company's press releases regularly (see Figure 3).</p> <p>Figure 3 – BioNTech’s expected pipeline milestones in 2022</p> <p><figure><picture> <img loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2022/4/55366256_16493191884372_rId17.png\"/> </picture><figcaption><p><span>BioNTech's 2021 investor presentation</span></p></figcaption></figure></p> <h2>Summary</h2> <p>According to BioNTech’s guidance as of Nov 2021, the company expected FY 2021 revenue of €16 to €17 billion. The company’s FY 2021 actual revenue beat the expectation by 12%. BioNTech expects FY 2022 revenue of €14 to €17 billion. However, I estimate FY 2022 revenue of €19 billion for the German company. Also, based on my valuation, BNTX is undervalued at its current price. In a word, I am bullish on the stock.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech: Buy The Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech: Buy The Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 18:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4500401-biontech-buy-the-dip><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U. J. Alexander/iStock Editorial via Getty Images BioNTech SE (NASDAQ:BNTX) is worth a lot more than its current price. A year ago, BNTX's stock price was around $110. BNTX's stock price jumped from $...</p>\n\n<a href=\"https://seekingalpha.com/article/4500401-biontech-buy-the-dip\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","GILD":"吉利德科学","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4578":"CAR-T","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4551":"寇图资本持仓","CCA":"MFS California Municipal Fund","MRNA":"Moderna, Inc.","BIIB":"渤健公司","BK4581":"高盛持仓","BNTX":"BioNTech SE","BK4548":"巴美列捷福持仓"},"source_url":"https://seekingalpha.com/article/4500401-biontech-buy-the-dip","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2225289895","content_text":"U. J. Alexander/iStock Editorial via Getty Images BioNTech SE (NASDAQ:BNTX) is worth a lot more than its current price. A year ago, BNTX's stock price was around $110. BNTX's stock price jumped from $113 on 7 April 2021 to $447 on 9 August 2021. Since then, the stock’s price dropped 63%, even as the company reported strong 3Q 2021 and 4Q 2021 financial results. I estimate the stock is worth $264, implying a 56% upside potential. According to Seeking Alpha ratings (Wall Street price target), BNTX has a low price target of $164, a median price target of $251, and a high price target of $396. Also, according to Seeking Alpha quant rating, the stock is a Strong Buy. 4Q 2021 results In its 4Q 2021 financial result, BioNTech reported total revenue of €5.5b, compared with 4Q 2020 total revenue of €345m, up 1500%. The company’s FY 2021 revenue grew more than 3800% YoY. BNTX reported a profit of €12.18 per diluted share in the fourth quarter of 2021, compared with a 4Q 2020 profit of €1.43 per diluted share. BioNTech’s net profit jumped from €15.2m in 2020 to €10.3b in 2021. In 2021, about 2.6 billion doses of Pfizer/BioNTech COVID-19 vaccine delivered to more than 165 countries. BioNTech increased its research and development expenses from €645m in 2020 to €949m in 2021, up 47%. BNTX's loans and borrowings jumped to more than €129m in 2021, up 1430% YoY. The company's total current liabilities increased from €606m in 2020 to €3482m in 2021. Moreover, on 31 March 2021, BioNTech announced entering into a share repurchase program, worth $1.5b over the next two years. Estimation of BNTX’s 2022 vaccine delivery and 1Q 2022 revenue In 2021, around 9 billion COVID-19 vaccine doses administered globally. Also, in 2021, 2.6 billion Pfizer/BioNTech vaccine doses delivered to more than 165 countries. Accounting for the time lag between providing and administering the vaccine doses, I estimate a 25% market share for Pfizer/BioNTech COVID-19 vaccine. BioNTech and Pfizer signed orders to manufacture 2.4 billion COVID-19 vaccine doses in 2022. I estimate there will be more orders in the next nine months. As of 6 April 2022, 4.98 billion people have received the COVID-19 vaccine worldwide (Table 1). According to the Bloomberg vaccine tracker, at the current pace of vaccination, “it will take another nine months until 75% of the population has received at least one dose.” I estimate 2.657 billion doses of BNT162b2 will be delivered by the end of 2022. I should notice that my estimation is based on the assumption that 50% of the world population will receive the third dose of the COVID-19 vaccine, and 10% will receive the fourth dose of the COVID-19 vaccine by the end of 2022. On 29 March 2022, BioNTech reported that FDA authorized the second booster dose of the COVID-19 vaccine in individuals aged 50 years and older. In a few months, there might be authorization for the second booster dose in individuals aged below 50. Table 1 – Estimation of Pfizer/BioNTech vaccine delivery in 2022   Author's calculations In its fourth-quarter and full-year 2021 financial result and corporate update, BioNTech reiterated BioNTech COVID-19 vaccine revenue guidance of €13 billion to €17 billion. I estimate that if the world increases the pace of administering the first and second boosters of the COVID-19 vaccine in the next nine months, BioNTech’s full-year 2022 vaccine revenue may reach €19 billion. Also, based on quarterly results, I estimate a 1Q 2022 revenue of €5.3 billion for BioNTech (Table 2). Table 2 - 1Q 2022 revenue estimation   Author's calculations based on BioNTech's quarterly financial reports Figure 1 shows that in European Union and the United States, Pfizer/BioNTech vaccine is the most administered vaccine. According to ourworldindata.org, as of 28 March 2022, 77% of Pfizer/BioNTech vaccine administration globally belongs to the European Union and the United States. Also, respectively, 59% and 72% of vaccines administered in the United States and the European Union are manufactured by Pfizer/BioNTech. Furthermore, respectively, 61% (74 million doses) and 95% (87 million doses) of vaccine doses administered in South Korea and Japan were manufactured by Pfizer/BioNTech. Figure 1 - COVID-19 vaccine doses administered by manufacturer, European Union and United States   ourworldindata.org Performance From now, the numbers are in US$ as I use Seeking Alpha’s data in the performance section and valuation section. In the following section, I provided a detailed analysis of BioNTech’s capital structure for those readers who wish to scratch beneath the surface. In 2021, BNTX saw a very impressive 97% higher cash which was $2392.7m, versus the previous result of $1210.2m in 2020. The company’s debt increased in 2021 and sat at $286.7m, which is about 19% higher than its level of $240.2m at the end of 2020. Also, it is worth mentioning that BNTX’s equity surged amazingly during 2021 and sat at $8711.5m versus its level of $1371.8m at the end of 2020 (see Table 3). Table 3 – BioNTech’s capital structure   Author Analyzing BioNTech’s R&D to revenue during the recent years and comparing it with its peers, we observe that BNTX had the least amount among its competitors. This ratio measures the amount of revenue that is related to research and development expenditures (see Table 4). In a word, the current strong financial conditions and low leverage ratios will likely bring considerable improvements during 2022. Table 4 – BioNTech’s R&D/revenue ratio vs. its peers.   Author Valuation Using Comparable Company Analysis (CCA), I evaluated that BioNTech stock is attractive and undervalued. Comparing BioNTech SE with other peer competitors – Gilead Sciences (GILD), Moderna (MRNA), Biogen Inc. (BIIB) - and using the CCA method, I estimate that the stock's fair value is $265. This method reflects the real-market data and is an appropriate way of analyzing BioNTech due to the company’s stability. In the case of choosing competitors, I considered biotechnology companies with similar research and development fields, size, and profitability. Data was gathered from the most recent quarterly and TTM data. Analyzing other companies' ratios and comparing them with BNTX's, we can figure out that BioNTech looks relatively attractive and it is undervalued. The company's P/E ratio is 3.95x, which is far lower than the peer’s average of 6.95x. A stock with a lower P/E ratio is a value stock because it indicates that investors are paying less for every dollar of earnings they receive. Furthermore, the company’s EV/EBITDA is 3.73x compared with the peer’s average of 6.34x. In a word, the lower the EV/EBITDA, the cheaper the price for a company (see Figure 2). Figure 2 – BioNTech’s financial ratios vs. its peers   Author Besides BioNTech, I have done some analysis on the peer companies. Moderna's EV/EBIT amount is 3.44x, which is far lower than the peer's average. Also, Biogen’s EV/EBITDA is 8.61x, which is 34% higher than the group's average of 6.38x. Generally speaking, the higher EV/EBITDA implies that Biogen is potentially overvalued. Despite observing drops in BNTX's per-share price recently, using the CCA method, I evaluate that BNTX stock is potentially undervalued and has a considerable upside potential - a fair value of $265 (see Table 5). Table 5 – BNTX stock valuation based on CCA method Author's calculations Risks BioNTech benefited from the pandemic in 2021. However, from now on, everything depends on the third dose and fourth dose of the COVID-19 vaccine. The company expects to release the data for the third dose regimen in children aged 6 months to 5 years in a few weeks. Also, BioNTech has not released the data for the fourth dose of the COVID-19 vaccine in adults aged 16 to 65 years. The time of data release for the third dose in children aged 5 years to 12 years is not determined yet. Also, BioNTech is working on the next generation of COVID-19 vaccines. It expects to release the data for the Omicron-based vaccine in a few weeks. In the second half of 2022, the company will release multiple updates on variant combinations and bivalent vaccines. There will be updates on the Influenza mRNA vaccine, infectious diseases vaccines, and oncology programs in the second half of 2022. Thus, as much as progress in any of the mentioned fields could help the company, bad news may cause the stock price to drop. Make sure you follow the company's press releases regularly (see Figure 3). Figure 3 – BioNTech’s expected pipeline milestones in 2022   BioNTech's 2021 investor presentation Summary According to BioNTech’s guidance as of Nov 2021, the company expected FY 2021 revenue of €16 to €17 billion. The company’s FY 2021 actual revenue beat the expectation by 12%. BioNTech expects FY 2022 revenue of €14 to €17 billion. However, I estimate FY 2022 revenue of €19 billion for the German company. Also, based on my valuation, BNTX is undervalued at its current price. In a word, I am bullish on the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9016878545,"gmtCreate":1649171521379,"gmtModify":1676534463315,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>⛽⛽jiayou! Soar more please! 💪💪💪","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>⛽⛽jiayou! Soar more please! 💪💪💪","text":"$BioNTech SE(BNTX)$⛽⛽jiayou! Soar more please! 💪💪💪","images":[{"img":"https://community-static.tradeup.com/news/eb0a3a5238dc8ff914516ea833343ad1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016878545","isVote":1,"tweetType":1,"viewCount":447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9030362414,"gmtCreate":1645638922272,"gmtModify":1676534047883,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Still holding on, com'on!!!","listText":"Still holding on, com'on!!!","text":"Still holding on, com'on!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030362414","repostId":"2213875992","repostType":2,"repost":{"id":"2213875992","kind":"news","pubTimestamp":1645636541,"share":"https://ttm.financial/m/news/2213875992?lang=&edition=fundamental","pubTime":"2022-02-24 01:15","market":"us","language":"en","title":"BioNTech a buy at Wainwright, but price target lowered on long-term vaccine sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2213875992","media":"seekingalpha","summary":"Thomas Lohnes/Getty Images News   H.C. Wainwright is maintaining its buy rating on BioNTech (BNTX -3","content":"<html><body><p><figure> <picture> <img height=\"1022px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284941928/image_1284941928.jpg?io=getty-c-w240 240w\" width=\"1536px\"/> </picture> <figcaption><p>Thomas Lohnes/Getty Images News</p></figcaption> </figure></p> <ul> <li>H.C. Wainwright is maintaining its buy rating on BioNTech (BNTX <span>-3.5%</span>), but is lowering its price target due to<span> concerns on long-term sales of the company's COVID-19 vaccine.</span> </li> <li>The firm now has a price target of $339, down from $366 (~126% upside based on Tuesday's close).</li> <li>\"While we believe that continuing expansion of vaccine authorizations into younger populations, the continued deployment of booster vaccines due to waning anti-SARSCoV-2 vaccine-induced immunity over time, and the possible near-term availability of an Omicron-specific vaccine may all buoy vaccine sales near-term, the possibility of transition to endemic status for the COVID-19 pandemic poses a long-term risk to the Comirnaty franchise because this may reduce population willingness to endure frequent vaccine shots,\" said analyst Robert Burns.</li> <li>While the demand for the shots, which are marketed with partner Pfizer (PFE <span>-0.4%</span>), may still persist as the pandemic enters the endemic stage, it could became substantially lower, he added.</li> <li>Read why Seeking Alpha contributor Edmund Ingham just wrote that BioNTech (BNTX <span>-3.5%</span>) is a sell.</li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech a buy at Wainwright, but price target lowered on long-term vaccine sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech a buy at Wainwright, but price target lowered on long-term vaccine sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-24 01:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3804324-biontech-a-buy-at-wainwright-but-price-target-lowered-on-long-term-vaccine-sales><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thomas Lohnes/Getty Images News   H.C. Wainwright is maintaining its buy rating on BioNTech (BNTX -3.5%), but is lowering its price target due to concerns on long-term sales of the company's COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3804324-biontech-a-buy-at-wainwright-but-price-target-lowered-on-long-term-vaccine-sales\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4534":"瑞士信贷持仓","BNTX":"BioNTech SE","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3804324-biontech-a-buy-at-wainwright-but-price-target-lowered-on-long-term-vaccine-sales","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2213875992","content_text":"Thomas Lohnes/Getty Images News   H.C. Wainwright is maintaining its buy rating on BioNTech (BNTX -3.5%), but is lowering its price target due to concerns on long-term sales of the company's COVID-19 vaccine.  The firm now has a price target of $339, down from $366 (~126% upside based on Tuesday's close). \"While we believe that continuing expansion of vaccine authorizations into younger populations, the continued deployment of booster vaccines due to waning anti-SARSCoV-2 vaccine-induced immunity over time, and the possible near-term availability of an Omicron-specific vaccine may all buoy vaccine sales near-term, the possibility of transition to endemic status for the COVID-19 pandemic poses a long-term risk to the Comirnaty franchise because this may reduce population willingness to endure frequent vaccine shots,\" said analyst Robert Burns. While the demand for the shots, which are marketed with partner Pfizer (PFE -0.4%), may still persist as the pandemic enters the endemic stage, it could became substantially lower, he added. Read why Seeking Alpha contributor Edmund Ingham just wrote that BioNTech (BNTX -3.5%) is a sell.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096168330,"gmtCreate":1644331993274,"gmtModify":1676533913547,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Why?????","listText":"Why?????","text":"Why?????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096168330","repostId":"1134821430","repostType":2,"repost":{"id":"1134821430","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644331420,"share":"https://ttm.financial/m/news/1134821430?lang=&edition=fundamental","pubTime":"2022-02-08 22:43","market":"us","language":"en","title":"Vaccine Stocks Slipped in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134821430","media":"Tiger Newspress","summary":"Vaccine stocks slipped in morning trading, with Novavax down 9.49% and Moderna down 3.58%.Novavax In","content":"<html><head></head><body><p>Vaccine stocks slipped in morning trading, with Novavax down 9.49% and Moderna down 3.58%.<img src=\"https://static.tigerbbs.com/fe2f590c6710bfc4675b4251f99cea74\" tg-width=\"377\" tg-height=\"399\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax Inc</a> has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government&#39;s vaccine rollouts told Reuters.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slipped in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slipped in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-08 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks slipped in morning trading, with Novavax down 9.49% and Moderna down 3.58%.<img src=\"https://static.tigerbbs.com/fe2f590c6710bfc4675b4251f99cea74\" tg-width=\"377\" tg-height=\"399\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax Inc</a> has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government&#39;s vaccine rollouts told Reuters.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134821430","content_text":"Vaccine stocks slipped in morning trading, with Novavax down 9.49% and Moderna down 3.58%.Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government's vaccine rollouts told Reuters.","news_type":1},"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9090031998,"gmtCreate":1643032784324,"gmtModify":1676533766605,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵","text":"$BioNTech SE(BNTX)$Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵","images":[{"img":"https://static.itradeup.com/news/7c2c5fbc8ccfdfbf8881b22c3b5220af","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090031998","isVote":1,"tweetType":1,"viewCount":1525,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3563196147337980","authorId":"3563196147337980","name":"wanyan","avatar":"https://static.tigerbbs.com/5cd6127ccb204f5f868bc820cb45e234","crmLevel":1,"crmLevelSwitch":0,"idStr":"3563196147337980","authorIdStr":"3563196147337980"},"content":"hold on tight... don't see until they release new vaccine","text":"hold on tight... don't see until they release new vaccine","html":"hold on tight... don't see until they release new vaccine"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9004375853,"gmtCreate":1642518500039,"gmtModify":1676533718176,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Guess really need to hang on for a while more to see where this is going&nbsp; &nbsp;&nbsp;","listText":"Guess really need to hang on for a while more to see where this is going&nbsp; &nbsp;&nbsp;","text":"Guess really need to hang on for a while more to see where this is going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004375853","repostId":"1159142841","repostType":2,"repost":{"id":"1159142841","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642516584,"share":"https://ttm.financial/m/news/1159142841?lang=&edition=fundamental","pubTime":"2022-01-18 22:36","market":"us","language":"en","title":"BioNTech shares tumbled nearly 8% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1159142841","media":"Tiger Newspress","summary":"BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omic","content":"<html><head></head><body><p>BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omicron waning in a week.<img src=\"https://static.tigerbbs.com/820a316803b5a9c6361c44c1007ab003\" tg-width=\"865\" tg-height=\"641\" width=\"100%\" height=\"auto\"/>Israel will continue to offer a fourth COVID-19 vaccine shot despite preliminary findings that it is not enough to prevent Omicron infections, a senior health official said on Tuesday, predicting contagions stoked by the variant will wane in a week.</p><p>The fastest country to roll out vaccinations a year ago, Israel last month started offering a fourth shot - also known as a second booster - to its most vulnerable and high-risk groups.</p><p>A preliminary study published by an Israeli hospital on Monday found that the fourth shot increases antibodies to even higher levels than the third but &#34;probably&#34; not enough to fend off the highly transmissible Omicron.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech shares tumbled nearly 8% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech shares tumbled nearly 8% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-18 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omicron waning in a week.<img src=\"https://static.tigerbbs.com/820a316803b5a9c6361c44c1007ab003\" tg-width=\"865\" tg-height=\"641\" width=\"100%\" height=\"auto\"/>Israel will continue to offer a fourth COVID-19 vaccine shot despite preliminary findings that it is not enough to prevent Omicron infections, a senior health official said on Tuesday, predicting contagions stoked by the variant will wane in a week.</p><p>The fastest country to roll out vaccinations a year ago, Israel last month started offering a fourth shot - also known as a second booster - to its most vulnerable and high-risk groups.</p><p>A preliminary study published by an Israeli hospital on Monday found that the fourth shot increases antibodies to even higher levels than the third but &#34;probably&#34; not enough to fend off the highly transmissible Omicron.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159142841","content_text":"BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omicron waning in a week.Israel will continue to offer a fourth COVID-19 vaccine shot despite preliminary findings that it is not enough to prevent Omicron infections, a senior health official said on Tuesday, predicting contagions stoked by the variant will wane in a week.The fastest country to roll out vaccinations a year ago, Israel last month started offering a fourth shot - also known as a second booster - to its most vulnerable and high-risk groups.A preliminary study published by an Israeli hospital on Monday found that the fourth shot increases antibodies to even higher levels than the third but \"probably\" not enough to fend off the highly transmissible Omicron.","news_type":1},"isVote":1,"tweetType":1,"viewCount":516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002939190,"gmtCreate":1641880185727,"gmtModify":1676533658468,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Pfizer CEO says Omicron-targeted vaccine is most likely outcome&nbsp;&nbsp;http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&amp;utm_medium=social-media&amp;utm_campaign=native-share","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Pfizer CEO says Omicron-targeted vaccine is most likely outcome&nbsp;&nbsp;http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&amp;utm_medium=social-media&amp;utm_campaign=native-share","text":"$BioNTech SE(BNTX)$Pfizer CEO says Omicron-targeted vaccine is most likely outcome http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&utm_medium=social-media&utm_campaign=native-share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002939190","isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008585214,"gmtCreate":1641482637853,"gmtModify":1676533620097,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Precisely...why are investors selling now, pushing the price to an all time low...","listText":"Precisely...why are investors selling now, pushing the price to an all time low...","text":"Precisely...why are investors selling now, pushing the price to an all time low...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008585214","repostId":"1137932427","repostType":4,"repost":{"id":"1137932427","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641482309,"share":"https://ttm.financial/m/news/1137932427?lang=&edition=fundamental","pubTime":"2022-01-06 23:18","market":"us","language":"en","title":"Vaccine Stocks Slid in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1137932427","media":"Tiger Newspress","summary":"Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell b","content":"<html><head></head><body><p>Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/a275eb7fdd60e6ddf615caa2e0c8a763\" tg-width=\"285\" tg-height=\"274\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slid in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slid in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-06 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/a275eb7fdd60e6ddf615caa2e0c8a763\" tg-width=\"285\" tg-height=\"274\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137932427","content_text":"Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008589376,"gmtCreate":1641482049506,"gmtModify":1676533619975,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭","text":"$BioNTech SE(BNTX)$Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭","images":[{"img":"https://static.itradeup.com/news/79deae1a9194c530a1c64e3f56f7f3e5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008589376","isVote":1,"tweetType":1,"viewCount":2064,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575196525040974","authorId":"3575196525040974","name":"lucidreams","avatar":"https://static.tigerbbs.com/7ac3b019946467eaf3bc2cddede15400","crmLevel":3,"crmLevelSwitch":0,"idStr":"3575196525040974","authorIdStr":"3575196525040974"},"content":"problem is omicron has a higher transmission rate leading to more infected,it has a lower hospitalisation rate. Unless a new deadly variant emerges.The stock would still struggle.Have a nice day.","text":"problem is omicron has a higher transmission rate leading to more infected,it has a lower hospitalisation rate. Unless a new deadly variant emerges.The stock would still struggle.Have a nice day.","html":"problem is omicron has a higher transmission rate leading to more infected,it has a lower hospitalisation rate. Unless a new deadly variant emerges.The stock would still struggle.Have a nice day."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869739702,"gmtCreate":1632320972306,"gmtModify":1676530752302,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Happy!","listText":"Happy!","text":"Happy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869739702","repostId":"1143821004","repostType":4,"repost":{"id":"1143821004","kind":"news","pubTimestamp":1632320072,"share":"https://ttm.financial/m/news/1143821004?lang=&edition=fundamental","pubTime":"2021-09-22 22:14","market":"us","language":"en","title":"Apple sees 5M iPhone 13 pre-orders in China--report","url":"https://stock-news.laohu8.com/highlight/detail?id=1143821004","media":"seekingalpha","summary":"Barely $one$ week after unveiling the iPhone 13, $Apple$ is already seeing strong initial demand for its flagship product coming out of China.TheSouth China Morning $Post$reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple  Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company $JD.com$took more than 3 million","content":"<p>Barely <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after unveiling the iPhone 13, <a href=\"https://laohu8.com/S/AAPL\">Apple</a>&nbsp;is already seeing strong initial demand for its flagship product coming out of China.</p>\n<p>The<i>South China Morning <a href=\"https://laohu8.com/S/POST\">Post</a></i>reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. The<i>Post</i>said that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company <a href=\"https://laohu8.com/S/JD\">JD.com</a>(NASDAQ:JD)took more than 3 million iPhone 13 pre-order</p>\n<p>The four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.</p>\n<p>Earlier this week, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.</p>\n<p>Apple gained over 1% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ac2063b03f2196c3d0a449ab604bd718\" tg-width=\"972\" tg-height=\"561\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple sees 5M iPhone 13 pre-orders in China--report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple sees 5M iPhone 13 pre-orders in China--report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that ...</p>\n\n<a href=\"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1143821004","content_text":"Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company JD.com(NASDAQ:JD)took more than 3 million iPhone 13 pre-order\nThe four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.\nEarlier this week, Bank of America analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.\nApple gained over 1% in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860812520,"gmtCreate":1632151534160,"gmtModify":1676530713055,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","text":"$Apple(AAPL)$Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","images":[{"img":"https://static.tigerbbs.com/b0af89bb1574b432e8444f3f77f33d8f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860812520","isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":818774678,"gmtCreate":1630453360694,"gmtModify":1676530305384,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","listText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","text":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818774678","repostId":"818716571","repostType":1,"repost":{"id":818716571,"gmtCreate":1630449630993,"gmtModify":1676530303744,"author":{"id":"3552874562834581","authorId":"3552874562834581","name":"Kel1","avatar":"https://static.tigerbbs.com/85967b7114ebaa24185158560185f10b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3552874562834581","authorIdStr":"3552874562834581"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","text":"$BioNTech SE(BNTX)$Will this recover?","images":[{"img":"https://static.tigerbbs.com/05a1cc87ba51e480f080e8ee03874f6d","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818716571","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811408639,"gmtCreate":1630334341921,"gmtModify":1676530273704,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? ?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? ?","text":"$Apple(AAPL)$Could it go up to $159?/$160 mark? ?","images":[{"img":"https://static.tigerbbs.com/4598427e97b0516704e776ad6ac92d5c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/811408639","isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":835555011,"gmtCreate":1629728460633,"gmtModify":1676530114271,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Hopefully it will rise to about its pre-glory price of $480+?","listText":"Hopefully it will rise to about its pre-glory price of $480+?","text":"Hopefully it will rise to about its pre-glory price of $480+?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835555011","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839819716,"gmtCreate":1629138426235,"gmtModify":1676529943068,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>will it go to $160? To hold or sell?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>will it go to $160? To hold or sell?","text":"$Apple(AAPL)$will it go to $160? To hold or sell?","images":[{"img":"https://static.tigerbbs.com/d28cd1e227e2939062a78ffd74a079f3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839819716","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":839321095,"gmtCreate":1629123032917,"gmtModify":1676529938266,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","text":"$BioNTech SE(BNTX)$what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","images":[{"img":"https://static.tigerbbs.com/f48fe970fb82f2b25a061d030b7565cb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":78,"commentSize":27,"repostSize":1,"link":"https://ttm.financial/post/839321095","isVote":1,"tweetType":1,"viewCount":4105,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"262190804341046","authorId":"262190804341046","name":"Jason1205","avatar":"https://static.tigerbbs.com/a22c3af3bb938bf74c151660df1d68dd","crmLevel":9,"crmLevelSwitch":0,"idStr":"262190804341046","authorIdStr":"262190804341046"},"content":"because of Afghanistan?","text":"because of Afghanistan?","html":"because of Afghanistan?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":897013387,"gmtCreate":1628862601349,"gmtModify":1676529878607,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","listText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","text":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897013387","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://ttm.financial/m/news/1141206470?lang=&edition=fundamental","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894097920,"gmtCreate":1628776934260,"gmtModify":1676529851787,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Fantastic positive&nbsp; news! Keeping fingers crossed!","listText":"Fantastic positive&nbsp; news! Keeping fingers crossed!","text":"Fantastic positive news! Keeping fingers crossed!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894097920","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://ttm.financial/m/news/2158325931?lang=&edition=fundamental","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899866221,"gmtCreate":1628174152263,"gmtModify":1703502609116,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Sold it a day ago at a loss. Cut losses fast and place my bets elsewhere.","listText":"Sold it a day ago at a loss. Cut losses fast and place my bets elsewhere.","text":"Sold it a day ago at a loss. Cut losses fast and place my bets elsewhere.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899866221","repostId":"1121539393","repostType":4,"repost":{"id":"1121539393","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628171164,"share":"https://ttm.financial/m/news/1121539393?lang=&edition=fundamental","pubTime":"2021-08-05 21:46","market":"us","language":"en","title":"Lemonade drops over 12% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1121539393","media":"Tiger Newspress","summary":"(Aug 5)  Lemonade, Inc. stock drops over 12% after online insurers sales decline, losses widen.","content":"<p>(Aug 5)&nbsp; <a href=\"https://laohu8.com/S/LMND\">Lemonade, Inc.</a> stock drops over 12% after online insurers sales decline, losses widen.</p>\n<p><img src=\"https://static.tigerbbs.com/6825a39000754135d042cb3962be5c5b\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lemonade drops over 12% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLemonade drops over 12% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5)&nbsp; <a href=\"https://laohu8.com/S/LMND\">Lemonade, Inc.</a> stock drops over 12% after online insurers sales decline, losses widen.</p>\n<p><img src=\"https://static.tigerbbs.com/6825a39000754135d042cb3962be5c5b\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMND":"Lemonade, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121539393","content_text":"(Aug 5)  Lemonade, Inc. stock drops over 12% after online insurers sales decline, losses widen.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":839321095,"gmtCreate":1629123032917,"gmtModify":1676529938266,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","text":"$BioNTech SE(BNTX)$what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","images":[{"img":"https://static.tigerbbs.com/f48fe970fb82f2b25a061d030b7565cb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":78,"commentSize":27,"repostSize":1,"link":"https://ttm.financial/post/839321095","isVote":1,"tweetType":1,"viewCount":4105,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"262190804341046","authorId":"262190804341046","name":"Jason1205","avatar":"https://static.tigerbbs.com/a22c3af3bb938bf74c151660df1d68dd","crmLevel":9,"crmLevelSwitch":0,"idStr":"262190804341046","authorIdStr":"262190804341046"},"content":"because of Afghanistan?","text":"because of Afghanistan?","html":"because of Afghanistan?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9008589376,"gmtCreate":1641482049506,"gmtModify":1676533619975,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭","text":"$BioNTech SE(BNTX)$Seriously?! Omicron is wrecking havoc globally and vaccine stock falling like no tomorrow? What's up??? 😭","images":[{"img":"https://static.itradeup.com/news/79deae1a9194c530a1c64e3f56f7f3e5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008589376","isVote":1,"tweetType":1,"viewCount":2064,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575196525040974","authorId":"3575196525040974","name":"lucidreams","avatar":"https://static.tigerbbs.com/7ac3b019946467eaf3bc2cddede15400","crmLevel":3,"crmLevelSwitch":0,"idStr":"3575196525040974","authorIdStr":"3575196525040974"},"content":"problem is omicron has a higher transmission rate leading to more infected,it has a lower hospitalisation rate. Unless a new deadly variant emerges.The stock would still struggle.Have a nice day.","text":"problem is omicron has a higher transmission rate leading to more infected,it has a lower hospitalisation rate. Unless a new deadly variant emerges.The stock would still struggle.Have a nice day.","html":"problem is omicron has a higher transmission rate leading to more infected,it has a lower hospitalisation rate. Unless a new deadly variant emerges.The stock would still struggle.Have a nice day."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9090031998,"gmtCreate":1643032784324,"gmtModify":1676533766605,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵","text":"$BioNTech SE(BNTX)$Speechless...can't dump, can't see a silver lining now...what can I do? 🤯😵","images":[{"img":"https://static.itradeup.com/news/7c2c5fbc8ccfdfbf8881b22c3b5220af","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090031998","isVote":1,"tweetType":1,"viewCount":1525,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3563196147337980","authorId":"3563196147337980","name":"wanyan","avatar":"https://static.tigerbbs.com/5cd6127ccb204f5f868bc820cb45e234","crmLevel":1,"crmLevelSwitch":0,"idStr":"3563196147337980","authorIdStr":"3563196147337980"},"content":"hold on tight... don't see until they release new vaccine","text":"hold on tight... don't see until they release new vaccine","html":"hold on tight... don't see until they release new vaccine"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":808478047,"gmtCreate":1627608292589,"gmtModify":1703493242770,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>OMG! SOMEONE PLEASE TELL me this stock will soar soon and not plummet further...to sell or not to sell now?","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>OMG! SOMEONE PLEASE TELL me this stock will soar soon and not plummet further...to sell or not to sell now?","text":"$Pinterest, Inc.(PINS)$OMG! SOMEONE PLEASE TELL me this stock will soar soon and not plummet further...to sell or not to sell now?","images":[{"img":"https://static.tigerbbs.com/d3f4c62fda66a6d444a2407e7ba7c2c7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/808478047","isVote":1,"tweetType":1,"viewCount":1641,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573684056944075","authorId":"3573684056944075","name":"HuatRocket","avatar":"https://community-static.tradeup.com/news/96f83f4d280b89b81386745f0a7b9d8d","crmLevel":3,"crmLevelSwitch":1,"idStr":"3573684056944075","authorIdStr":"3573684056944075"},"content":"have faith in this company... is just short term shorting by traders. it will soon grow back as future is all about surfing the internet","text":"have faith in this company... is just short term shorting by traders. it will soon grow back as future is all about surfing the internet","html":"have faith in this company... is just short term shorting by traders. it will soon grow back as future is all about surfing the internet"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":894097920,"gmtCreate":1628776934260,"gmtModify":1676529851787,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Fantastic positive&nbsp; news! Keeping fingers crossed!","listText":"Fantastic positive&nbsp; news! Keeping fingers crossed!","text":"Fantastic positive news! Keeping fingers crossed!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894097920","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://ttm.financial/m/news/2158325931?lang=&edition=fundamental","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008585214,"gmtCreate":1641482637853,"gmtModify":1676533620097,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Precisely...why are investors selling now, pushing the price to an all time low...","listText":"Precisely...why are investors selling now, pushing the price to an all time low...","text":"Precisely...why are investors selling now, pushing the price to an all time low...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008585214","repostId":"1137932427","repostType":4,"repost":{"id":"1137932427","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641482309,"share":"https://ttm.financial/m/news/1137932427?lang=&edition=fundamental","pubTime":"2022-01-06 23:18","market":"us","language":"en","title":"Vaccine Stocks Slid in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1137932427","media":"Tiger Newspress","summary":"Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell b","content":"<html><head></head><body><p>Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/a275eb7fdd60e6ddf615caa2e0c8a763\" tg-width=\"285\" tg-height=\"274\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slid in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slid in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-06 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/a275eb7fdd60e6ddf615caa2e0c8a763\" tg-width=\"285\" tg-height=\"274\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137932427","content_text":"Vaccine stocks slid in morning trading. BioNTech SE, Moderna, Pfizer, Histogenics and Novavax fell between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801200884,"gmtCreate":1627517023748,"gmtModify":1703491399368,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...any chance of a lift-up?&nbsp;","listText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...any chance of a lift-up?&nbsp;","text":"$Lemonade, Inc.(LMND)$sigh...any chance of a lift-up?","images":[{"img":"https://static.tigerbbs.com/74964a2fe535cbfb8cc997e1bd52365d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/801200884","isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3570969905136063","authorId":"3570969905136063","name":"BluesyB","avatar":"https://static.tigerbbs.com/08ef378f4bf73e911f916e9158d59de7","crmLevel":2,"crmLevelSwitch":0,"idStr":"3570969905136063","authorIdStr":"3570969905136063"},"content":"Dont give up. You are not alone","text":"Dont give up. You are not alone","html":"Dont give up. You are not alone"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":155359063,"gmtCreate":1625379288252,"gmtModify":1703741059433,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Good article, thanks!","listText":"Good article, thanks!","text":"Good article, thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155359063","repostId":"1160702483","repostType":4,"repost":{"id":"1160702483","kind":"news","pubTimestamp":1625369888,"share":"https://ttm.financial/m/news/1160702483?lang=&edition=fundamental","pubTime":"2021-07-04 11:38","market":"us","language":"en","title":"Two new stock market acronyms — FOLO and YOMO — can save you a lot of grief (and money)","url":"https://stock-news.laohu8.com/highlight/detail?id=1160702483","media":"MarketWatch","summary":"When stock market investing gets too easy, consider getting out of the market.\n\nYou’ve probably hear","content":"<blockquote>\n <b>When stock market investing gets too easy, consider getting out of the market.</b>\n</blockquote>\n<p>You’ve probably heard about people trading stocks based on two acronyms: FOMO (fear of missing out) and YOLO (you only live once). I searched Twitter for both terms with the word “stocks” included, and here’s what I found:</p>\n<p><img src=\"https://static.tigerbbs.com/4416d357ac2bc16d4fdcf60a3c4c3c56\" tg-width=\"916\" tg-height=\"463\"></p>\n<p>I have a proposition for you. In the name of flipping it, we should consider the following two terms as much more insightful and helpful to investors and traders:</p>\n<p>FOLO (fear of living once)&nbsp; and YOMO (you only miss out).</p>\n<p>Here’s a story I’ve told about how things can go wrong even when you’re think you’re trading well and outperforming the markets seems easy.</p>\n<p>Return to 2004</p>\n<p>It was late January 2004, and I was starting my second full year of running a hedge fund, and I was off to an incredible start to the year. I’d come into 2004 steadily scaling into ever-larger and more aggressive positions in mostly internet core equipment vendors like Nortel, JDSU, and Cisco, not to mention my largest position in Apple, which I’d first bought for the fund back in March of 2003. (I held Apple along with occasional Apple call options until I closed the fund, by the way.) I’d made big money already in my hedge fund, which was full of mostly long positions as the markets had been in a big rebound from their October 2002 lows.</p>\n<p>As 2004 started, the markets were in what I called a Steady Betty Rally Mode at the time, and internet-equipment stocks were the single hottest sector into the new year. I started trimming some of my biggest winners down, including the aforementioned Nortel, JDSU and Cisco, along with any stocks that were up 20%, 30% or even more as January wore on. By late January, I was nearly back up to half in cash and the hedge fund was already up nearly 25% for the year while the broader markets were barely up 5% on the year.</p>\n<p>In the last week of January, the markets turned south and the highest-flying winners of the year, like those that I’d just sold down and taken huge profits on, were the hardest hit. I’d previously learned the hard way over the years that you should never confuse a bull market with genius, but I’d even nailed the near-term top and my whole year was already in the pocket. I was feeling pretty good about myself and my trading prowess and listening to Willie cover Woody Guthrie’s classic, “Stay a little longer” chuckling about how I’d left before the party was busted!</p>\n<p>By early February, I was “only” up just over 20% on the year, as I still had half my fund in stocks and a few options, but the markets were now down year to date and the stocks I’d so smartly sold down at the top had themselves pulled back 20%-30% from their highs. They finally were stabilizing and the charts started to turn upward as the stocks were flattish to down on the year.</p>\n<p>Here I was sitting on a huge pile of cash and feeling like a genius for having sold at the top and here was a chance to just slowly start rebuilding and buying some new stocks while they were down. I started to buy back a few shares and to put just a little bit of that 50% cash, along with more cash coming in, to work in the markets.</p>\n<p>By the time March rolled around, I was back fully invested and mostly long, up single digits on the year, and the markets were down about 10% or so on the year. One morning as I walked into my hedge fund hotel office that I rented from Bear Stearns on the 40th floor in midtown New York, I was shocked to see the Nasdaq futures were down huge. I pulled up the Bloomberg terminal and my heart sank as the headline screamed “Nortel admits fraud; Major telecom equipment vendors under investigation” or something along those lines. Nortel was cut in half and most every internet-equipment-related stock in the market was down 20% or more on the day. I puked my guts out that whole day and cried myself to sleep that night.</p>\n<p>I spent the rest of the year digging out of that hole and getting back ahead of the market and had a lot of success in that hedge fund from that bottom.</p>\n<p>Lesson of the week — do not dig yourself a hole, OK?</p>\n<p>Foreshadowing</p>\n<p>Here’s something I wrote in 2007, the last time I started turning from bullish to bearish and eventually traded my hedge fund for a TV gig right before the markets started tanking in late 2007: “Concerned about complacency” (May 3, 2007).</p>\n<p>Here’s an excerpt:</p>\n<p><i>I’m worried. That’s no news flash, as I’m&nbsp;always&nbsp;worried, but I am really concerned about the complacency out there. Earnings are great, as evidenced by the booming season we’re experiencing. The global economy is lifting a lot of boats. And every time I try to get bearish, I feel almost silly when the action, fundamentals and environment are this strong.</i></p>\n<p><i>Just about everybody is long real estate. … Wasn’t almost every rationalization for why we shouldn’t fret about any real estate bubble true when real estate crashed the last few times?</i></p>\n<p><i>Last month, the IMF reported that “the global economy remains on track for robust growth in 2007 and 2008. … Moreover, downside risks to the outlook seem less threatening than at the time of the September 2006&nbsp;World Economic Outlook.” Has the IMF ever gotten the outlook right?</i></p>\n<p><i>This utter disregard for risk permeates the sell side, too, as evidenced by this broker note from Bear this morning: “Worries —&nbsp;the market is running out of major concerns.” Not surprisingly, I suppose, I’m going to&nbsp;flip&nbsp;that statement as I find I have more major concerns about the market and economy today than I’ve had at any point in the past five years.</i></p>\n<p><i>A&nbsp;Citi&nbsp;board member recently told me that I had a “lot of guts” for having launched a tech fund in October 2002. I think you’d have to have a lot of guts to launch a tech fund in May 2007! I’m focusing more on the short side than anything else right now.</i></p>\n<p>Beware when things are too easy</p>\n<p>Cody&nbsp;back in real time, 2021. I’m not saying the markets are about to tank like they did in 2008. But I am saying, once again, that I know way too many random hard-working people who are convinced that they can make big money in cryptos and meme stocks and by trading, trading, trading.</p>\n<p>And all my analysis points to an unfortunate risk/reward set up for the aggressive bulls here.</p>\n<p>That story above about Nortel: I’m here to tell you that you won’t always get a chance to sell when the charts stop working. You don’t always get a chance to lock in your gains while you think it’s easy.</p>\n<p>I’ve been in this business, picking stocks and helping people manage their money for 25 years, and it seems obvious to me that trading and investing and making profits and keeping those profits is very hard to do over many years. There are times it seems easy. That’s often the best time to get cautious. Because if it really were easy, nobody would work their real jobs. We could all just trade stocks to each other all day and make all the money we need. Yeah, right.</p>\n<p>I have a new name or two I’m digging hard into this week, one in AI and another that’s trying to revolutionize long-term gig employment trends. Until then, I’m staying steady as she goes, even as so many others think YOLO and FOMO are just fun, little acronyms.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two new stock market acronyms — FOLO and YOMO — can save you a lot of grief (and money)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo new stock market acronyms — FOLO and YOMO — can save you a lot of grief (and money)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-04 11:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/two-new-stock-market-acronyms-folo-and-yomo-can-save-you-a-lot-of-grief-and-money-11625247142?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When stock market investing gets too easy, consider getting out of the market.\n\nYou’ve probably heard about people trading stocks based on two acronyms: FOMO (fear of missing out) and YOLO (you only ...</p>\n\n<a href=\"https://www.marketwatch.com/story/two-new-stock-market-acronyms-folo-and-yomo-can-save-you-a-lot-of-grief-and-money-11625247142?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/two-new-stock-market-acronyms-folo-and-yomo-can-save-you-a-lot-of-grief-and-money-11625247142?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160702483","content_text":"When stock market investing gets too easy, consider getting out of the market.\n\nYou’ve probably heard about people trading stocks based on two acronyms: FOMO (fear of missing out) and YOLO (you only live once). I searched Twitter for both terms with the word “stocks” included, and here’s what I found:\n\nI have a proposition for you. In the name of flipping it, we should consider the following two terms as much more insightful and helpful to investors and traders:\nFOLO (fear of living once)  and YOMO (you only miss out).\nHere’s a story I’ve told about how things can go wrong even when you’re think you’re trading well and outperforming the markets seems easy.\nReturn to 2004\nIt was late January 2004, and I was starting my second full year of running a hedge fund, and I was off to an incredible start to the year. I’d come into 2004 steadily scaling into ever-larger and more aggressive positions in mostly internet core equipment vendors like Nortel, JDSU, and Cisco, not to mention my largest position in Apple, which I’d first bought for the fund back in March of 2003. (I held Apple along with occasional Apple call options until I closed the fund, by the way.) I’d made big money already in my hedge fund, which was full of mostly long positions as the markets had been in a big rebound from their October 2002 lows.\nAs 2004 started, the markets were in what I called a Steady Betty Rally Mode at the time, and internet-equipment stocks were the single hottest sector into the new year. I started trimming some of my biggest winners down, including the aforementioned Nortel, JDSU and Cisco, along with any stocks that were up 20%, 30% or even more as January wore on. By late January, I was nearly back up to half in cash and the hedge fund was already up nearly 25% for the year while the broader markets were barely up 5% on the year.\nIn the last week of January, the markets turned south and the highest-flying winners of the year, like those that I’d just sold down and taken huge profits on, were the hardest hit. I’d previously learned the hard way over the years that you should never confuse a bull market with genius, but I’d even nailed the near-term top and my whole year was already in the pocket. I was feeling pretty good about myself and my trading prowess and listening to Willie cover Woody Guthrie’s classic, “Stay a little longer” chuckling about how I’d left before the party was busted!\nBy early February, I was “only” up just over 20% on the year, as I still had half my fund in stocks and a few options, but the markets were now down year to date and the stocks I’d so smartly sold down at the top had themselves pulled back 20%-30% from their highs. They finally were stabilizing and the charts started to turn upward as the stocks were flattish to down on the year.\nHere I was sitting on a huge pile of cash and feeling like a genius for having sold at the top and here was a chance to just slowly start rebuilding and buying some new stocks while they were down. I started to buy back a few shares and to put just a little bit of that 50% cash, along with more cash coming in, to work in the markets.\nBy the time March rolled around, I was back fully invested and mostly long, up single digits on the year, and the markets were down about 10% or so on the year. One morning as I walked into my hedge fund hotel office that I rented from Bear Stearns on the 40th floor in midtown New York, I was shocked to see the Nasdaq futures were down huge. I pulled up the Bloomberg terminal and my heart sank as the headline screamed “Nortel admits fraud; Major telecom equipment vendors under investigation” or something along those lines. Nortel was cut in half and most every internet-equipment-related stock in the market was down 20% or more on the day. I puked my guts out that whole day and cried myself to sleep that night.\nI spent the rest of the year digging out of that hole and getting back ahead of the market and had a lot of success in that hedge fund from that bottom.\nLesson of the week — do not dig yourself a hole, OK?\nForeshadowing\nHere’s something I wrote in 2007, the last time I started turning from bullish to bearish and eventually traded my hedge fund for a TV gig right before the markets started tanking in late 2007: “Concerned about complacency” (May 3, 2007).\nHere’s an excerpt:\nI’m worried. That’s no news flash, as I’m always worried, but I am really concerned about the complacency out there. Earnings are great, as evidenced by the booming season we’re experiencing. The global economy is lifting a lot of boats. And every time I try to get bearish, I feel almost silly when the action, fundamentals and environment are this strong.\nJust about everybody is long real estate. … Wasn’t almost every rationalization for why we shouldn’t fret about any real estate bubble true when real estate crashed the last few times?\nLast month, the IMF reported that “the global economy remains on track for robust growth in 2007 and 2008. … Moreover, downside risks to the outlook seem less threatening than at the time of the September 2006 World Economic Outlook.” Has the IMF ever gotten the outlook right?\nThis utter disregard for risk permeates the sell side, too, as evidenced by this broker note from Bear this morning: “Worries — the market is running out of major concerns.” Not surprisingly, I suppose, I’m going to flip that statement as I find I have more major concerns about the market and economy today than I’ve had at any point in the past five years.\nA Citi board member recently told me that I had a “lot of guts” for having launched a tech fund in October 2002. I think you’d have to have a lot of guts to launch a tech fund in May 2007! I’m focusing more on the short side than anything else right now.\nBeware when things are too easy\nCody back in real time, 2021. I’m not saying the markets are about to tank like they did in 2008. But I am saying, once again, that I know way too many random hard-working people who are convinced that they can make big money in cryptos and meme stocks and by trading, trading, trading.\nAnd all my analysis points to an unfortunate risk/reward set up for the aggressive bulls here.\nThat story above about Nortel: I’m here to tell you that you won’t always get a chance to sell when the charts stop working. You don’t always get a chance to lock in your gains while you think it’s easy.\nI’ve been in this business, picking stocks and helping people manage their money for 25 years, and it seems obvious to me that trading and investing and making profits and keeping those profits is very hard to do over many years. There are times it seems easy. That’s often the best time to get cautious. Because if it really were easy, nobody would work their real jobs. We could all just trade stocks to each other all day and make all the money we need. Yeah, right.\nI have a new name or two I’m digging hard into this week, one in AI and another that’s trying to revolutionize long-term gig employment trends. Until then, I’m staying steady as she goes, even as so many others think YOLO and FOMO are just fun, little acronyms.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860812520,"gmtCreate":1632151534160,"gmtModify":1676530713055,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","text":"$Apple(AAPL)$Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","images":[{"img":"https://static.tigerbbs.com/b0af89bb1574b432e8444f3f77f33d8f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860812520","isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":811408639,"gmtCreate":1630334341921,"gmtModify":1676530273704,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? ?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? ?","text":"$Apple(AAPL)$Could it go up to $159?/$160 mark? ?","images":[{"img":"https://static.tigerbbs.com/4598427e97b0516704e776ad6ac92d5c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/811408639","isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9004375853,"gmtCreate":1642518500039,"gmtModify":1676533718176,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Guess really need to hang on for a while more to see where this is going&nbsp; &nbsp;&nbsp;","listText":"Guess really need to hang on for a while more to see where this is going&nbsp; &nbsp;&nbsp;","text":"Guess really need to hang on for a while more to see where this is going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004375853","repostId":"1159142841","repostType":2,"repost":{"id":"1159142841","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642516584,"share":"https://ttm.financial/m/news/1159142841?lang=&edition=fundamental","pubTime":"2022-01-18 22:36","market":"us","language":"en","title":"BioNTech shares tumbled nearly 8% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1159142841","media":"Tiger Newspress","summary":"BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omic","content":"<html><head></head><body><p>BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omicron waning in a week.<img src=\"https://static.tigerbbs.com/820a316803b5a9c6361c44c1007ab003\" tg-width=\"865\" tg-height=\"641\" width=\"100%\" height=\"auto\"/>Israel will continue to offer a fourth COVID-19 vaccine shot despite preliminary findings that it is not enough to prevent Omicron infections, a senior health official said on Tuesday, predicting contagions stoked by the variant will wane in a week.</p><p>The fastest country to roll out vaccinations a year ago, Israel last month started offering a fourth shot - also known as a second booster - to its most vulnerable and high-risk groups.</p><p>A preliminary study published by an Israeli hospital on Monday found that the fourth shot increases antibodies to even higher levels than the third but &#34;probably&#34; not enough to fend off the highly transmissible Omicron.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech shares tumbled nearly 8% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech shares tumbled nearly 8% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-18 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omicron waning in a week.<img src=\"https://static.tigerbbs.com/820a316803b5a9c6361c44c1007ab003\" tg-width=\"865\" tg-height=\"641\" width=\"100%\" height=\"auto\"/>Israel will continue to offer a fourth COVID-19 vaccine shot despite preliminary findings that it is not enough to prevent Omicron infections, a senior health official said on Tuesday, predicting contagions stoked by the variant will wane in a week.</p><p>The fastest country to roll out vaccinations a year ago, Israel last month started offering a fourth shot - also known as a second booster - to its most vulnerable and high-risk groups.</p><p>A preliminary study published by an Israeli hospital on Monday found that the fourth shot increases antibodies to even higher levels than the third but &#34;probably&#34; not enough to fend off the highly transmissible Omicron.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159142841","content_text":"BioNTech shares tumbled nearly 8% in morning trading. Israel sticks with 4th vaccine shot, sees Omicron waning in a week.Israel will continue to offer a fourth COVID-19 vaccine shot despite preliminary findings that it is not enough to prevent Omicron infections, a senior health official said on Tuesday, predicting contagions stoked by the variant will wane in a week.The fastest country to roll out vaccinations a year ago, Israel last month started offering a fourth shot - also known as a second booster - to its most vulnerable and high-risk groups.A preliminary study published by an Israeli hospital on Monday found that the fourth shot increases antibodies to even higher levels than the third but \"probably\" not enough to fend off the highly transmissible Omicron.","news_type":1},"isVote":1,"tweetType":1,"viewCount":516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002939190,"gmtCreate":1641880185727,"gmtModify":1676533658468,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Pfizer CEO says Omicron-targeted vaccine is most likely outcome&nbsp;&nbsp;http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&amp;utm_medium=social-media&amp;utm_campaign=native-share","listText":"<a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>Pfizer CEO says Omicron-targeted vaccine is most likely outcome&nbsp;&nbsp;http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&amp;utm_medium=social-media&amp;utm_campaign=native-share","text":"$BioNTech SE(BNTX)$Pfizer CEO says Omicron-targeted vaccine is most likely outcome http://www.asiaone.com/world/pfizer-ceo-says-omicron-targeted-vaccine-most-likely-outcome?utm_source=mobileapp&utm_medium=social-media&utm_campaign=native-share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002939190","isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869739702,"gmtCreate":1632320972306,"gmtModify":1676530752302,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Happy!","listText":"Happy!","text":"Happy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869739702","repostId":"1143821004","repostType":4,"repost":{"id":"1143821004","kind":"news","pubTimestamp":1632320072,"share":"https://ttm.financial/m/news/1143821004?lang=&edition=fundamental","pubTime":"2021-09-22 22:14","market":"us","language":"en","title":"Apple sees 5M iPhone 13 pre-orders in China--report","url":"https://stock-news.laohu8.com/highlight/detail?id=1143821004","media":"seekingalpha","summary":"Barely $one$ week after unveiling the iPhone 13, $Apple$ is already seeing strong initial demand for its flagship product coming out of China.TheSouth China Morning $Post$reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple  Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company $JD.com$took more than 3 million","content":"<p>Barely <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after unveiling the iPhone 13, <a href=\"https://laohu8.com/S/AAPL\">Apple</a>&nbsp;is already seeing strong initial demand for its flagship product coming out of China.</p>\n<p>The<i>South China Morning <a href=\"https://laohu8.com/S/POST\">Post</a></i>reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. The<i>Post</i>said that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company <a href=\"https://laohu8.com/S/JD\">JD.com</a>(NASDAQ:JD)took more than 3 million iPhone 13 pre-order</p>\n<p>The four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.</p>\n<p>Earlier this week, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.</p>\n<p>Apple gained over 1% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ac2063b03f2196c3d0a449ab604bd718\" tg-width=\"972\" tg-height=\"561\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple sees 5M iPhone 13 pre-orders in China--report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple sees 5M iPhone 13 pre-orders in China--report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that ...</p>\n\n<a href=\"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1143821004","content_text":"Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company JD.com(NASDAQ:JD)took more than 3 million iPhone 13 pre-order\nThe four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.\nEarlier this week, Bank of America analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.\nApple gained over 1% in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803515657,"gmtCreate":1627447666379,"gmtModify":1703490166210,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>Are we fools to believe we did not buy lemons? ?","listText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>Are we fools to believe we did not buy lemons? ?","text":"$Lemonade, Inc.(LMND)$Are we fools to believe we did not buy lemons? ?","images":[{"img":"https://static.tigerbbs.com/f76495f183af361c81cae2ed09407afa","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803515657","isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":818774678,"gmtCreate":1630453360694,"gmtModify":1676530305384,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","listText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","text":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818774678","repostId":"818716571","repostType":1,"repost":{"id":818716571,"gmtCreate":1630449630993,"gmtModify":1676530303744,"author":{"id":"3552874562834581","authorId":"3552874562834581","name":"Kel1","avatar":"https://static.tigerbbs.com/85967b7114ebaa24185158560185f10b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3552874562834581","authorIdStr":"3552874562834581"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","text":"$BioNTech SE(BNTX)$Will this recover?","images":[{"img":"https://static.tigerbbs.com/05a1cc87ba51e480f080e8ee03874f6d","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818716571","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144626311,"gmtCreate":1626282306633,"gmtModify":1703757149206,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...is there a chance price will recover? ?","listText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...is there a chance price will recover? ?","text":"$Lemonade, Inc.(LMND)$sigh...is there a chance price will recover? ?","images":[{"img":"https://static.tigerbbs.com/497235e9b9d50221612d15e54678aa40","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/144626311","isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3555207146978406","authorId":"3555207146978406","name":"X_krycek","avatar":"https://static.tigerbbs.com/f6cf3c789f54221d0dd0c2e6fa6657b0","crmLevel":3,"crmLevelSwitch":0,"idStr":"3555207146978406","authorIdStr":"3555207146978406"},"content":"I am holding mine","text":"I am holding mine","html":"I am holding mine"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143091164,"gmtCreate":1625751779058,"gmtModify":1703747810043,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"No wonder...?","listText":"No wonder...?","text":"No wonder...?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/143091164","repostId":"1143211463","repostType":4,"repost":{"id":"1143211463","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625751059,"share":"https://ttm.financial/m/news/1143211463?lang=&edition=fundamental","pubTime":"2021-07-08 21:30","market":"us","language":"en","title":"Dow drops 400 points amid global economic recovery concerns, bond yields slide","url":"https://stock-news.laohu8.com/highlight/detail?id=1143211463","media":"Tiger Newspress","summary":"The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Cov","content":"<p>The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Covid-19. The losses came as Japandeclared a state of emergency in Tokyofor the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants.</p>\n<p>The Dow Jones Industrial Average dropped about 400 points, or 1.1% with losses increasing throughout the overnight session. The S&amp;P 500 lost 1.25%. The Nasdaq 100 Composite fell 1.6%. Both the S&amp;P 500 and Nasdaq Composite closed at records in the prior session because of gains from tech shares.</p>\n<p>The Labor Department'slatest jobless claims datacame in unexpectedly higher at 373,000, signaling a slowdown in the the labor picture amid the Covid recovery. Economists expected to see 350,000 first-time applicants for unemployment benefits for the week ended July 3, according to Dow Jones.</p>\n<p>Premarket losses were led by companies that would benefit from a rapid economic comeback from the virus. Shares ofCarnivalandRoyal Caribbeaneach dropped more than 3%.American AirlinesandDelta Air Lineseach fell more than 2% in early trading.Boeingfell 2%.FordandNikewere also lower. RetailersLowe'sandHome Depotalso dipped in premarket trading.</p>\n<p>Chip stocks also fell on concerns about the pace of the global recovery.Micron,NVIDIA,Qualcomm,IntelandApplied Materialsalso ticked lower in the premarket.</p>\n<p>\"The market has been in one of those 'Goldilocks' stretches when economic growth was accelerating while inflation and interest rates remained low.&nbsp;Increased Covid cases, particularly Delta Variants have caused concerns that the economic acceleration will slow,\" Timothy Lesko of Granite Investment Advisors told CNBC. \"A few weeks ago the porridge was too hot, now it seems it is too cold.&nbsp;With markets at all time highs and some valuations stretched there is little room for economic slowdown in this market.\"</p>\n<p>Investors rotated into the safety of Treasuries further on Thursday, pushing the yield on the10-year Treasurybelow 1.255% to the lowest since late February. Despite the recovering economy and fast inflation, the 10-year Treasury yield continues to decline. It was at 1.58% to start July and hit a 2021 high of 1.78% in March. Traders remain confused about the exact reasons for the rollover in yields, with many citing concern that the best of the economic recovery may be behind us.</p>\n<p>Bank of America,Wells Fargo,Goldman Sachsand other financial shares declined in premarket trading as their profitability outlook dimmed with lower rates.JPMorgan ChaseandPNC Financialwere also lower.</p>\n<p>\"Nothing suggests the near slump in yields is over,\" wrote Christopher Harvey, head of equity strategy at Wells Fargo, in a note Thursday. \"A sharp drop below 1.25% could cause equity PMs to believe that something is wrong or broken. As a result, we see a growing possibility of a 5% selloff in equities before earnings season.\"</p>\n<p>Harvey noted he believes the buying in bonds is more technical in nature and not due to macroeconomic factors.</p>\n<p>Spectatorscould be banned from the Olympic games, according to a report following the state of emergency declaration for Tokyo by Japan.</p>\n<p>Meanwhile the global Covid death toll continued to advance,exceeding 4 million on late Wednesday, as countries including India battle more transmissible variants.</p>\n<p>TheCboe Volatility index, or 'VIX,' surged above the key 20 level Thursday morning, perhaps signaling a period of greater volatility ahead.</p>\n<p>\"The 40 basis point decline in the yield on the benchmark 10-year Treasury note since late-March suggests that the global grab for yield remains a potent force, despite the Fed's desire to let the economy run hot,\" Steven Ricchiuto, U.S. chief economist at Mizuho Securities, wrote in a note this week.</p>\n<p>\"A stronger currency, increased virus concerns oversea, and the associated demand for long-term Treasury notes and bonds implies reduced inflation expectations and increased risk of importing global deflation,\" he added.</p>\n<p>So-called meme stocks took big hits on Thursday as the sell-off caused investors to flee stocks likeAMCandGameStopthat had been boosted by speculative trading by retail traders chatting on Reddit.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow drops 400 points amid global economic recovery concerns, bond yields slide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow drops 400 points amid global economic recovery concerns, bond yields slide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-08 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Covid-19. The losses came as Japandeclared a state of emergency in Tokyofor the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants.</p>\n<p>The Dow Jones Industrial Average dropped about 400 points, or 1.1% with losses increasing throughout the overnight session. The S&amp;P 500 lost 1.25%. The Nasdaq 100 Composite fell 1.6%. Both the S&amp;P 500 and Nasdaq Composite closed at records in the prior session because of gains from tech shares.</p>\n<p>The Labor Department'slatest jobless claims datacame in unexpectedly higher at 373,000, signaling a slowdown in the the labor picture amid the Covid recovery. Economists expected to see 350,000 first-time applicants for unemployment benefits for the week ended July 3, according to Dow Jones.</p>\n<p>Premarket losses were led by companies that would benefit from a rapid economic comeback from the virus. Shares ofCarnivalandRoyal Caribbeaneach dropped more than 3%.American AirlinesandDelta Air Lineseach fell more than 2% in early trading.Boeingfell 2%.FordandNikewere also lower. RetailersLowe'sandHome Depotalso dipped in premarket trading.</p>\n<p>Chip stocks also fell on concerns about the pace of the global recovery.Micron,NVIDIA,Qualcomm,IntelandApplied Materialsalso ticked lower in the premarket.</p>\n<p>\"The market has been in one of those 'Goldilocks' stretches when economic growth was accelerating while inflation and interest rates remained low.&nbsp;Increased Covid cases, particularly Delta Variants have caused concerns that the economic acceleration will slow,\" Timothy Lesko of Granite Investment Advisors told CNBC. \"A few weeks ago the porridge was too hot, now it seems it is too cold.&nbsp;With markets at all time highs and some valuations stretched there is little room for economic slowdown in this market.\"</p>\n<p>Investors rotated into the safety of Treasuries further on Thursday, pushing the yield on the10-year Treasurybelow 1.255% to the lowest since late February. Despite the recovering economy and fast inflation, the 10-year Treasury yield continues to decline. It was at 1.58% to start July and hit a 2021 high of 1.78% in March. Traders remain confused about the exact reasons for the rollover in yields, with many citing concern that the best of the economic recovery may be behind us.</p>\n<p>Bank of America,Wells Fargo,Goldman Sachsand other financial shares declined in premarket trading as their profitability outlook dimmed with lower rates.JPMorgan ChaseandPNC Financialwere also lower.</p>\n<p>\"Nothing suggests the near slump in yields is over,\" wrote Christopher Harvey, head of equity strategy at Wells Fargo, in a note Thursday. \"A sharp drop below 1.25% could cause equity PMs to believe that something is wrong or broken. As a result, we see a growing possibility of a 5% selloff in equities before earnings season.\"</p>\n<p>Harvey noted he believes the buying in bonds is more technical in nature and not due to macroeconomic factors.</p>\n<p>Spectatorscould be banned from the Olympic games, according to a report following the state of emergency declaration for Tokyo by Japan.</p>\n<p>Meanwhile the global Covid death toll continued to advance,exceeding 4 million on late Wednesday, as countries including India battle more transmissible variants.</p>\n<p>TheCboe Volatility index, or 'VIX,' surged above the key 20 level Thursday morning, perhaps signaling a period of greater volatility ahead.</p>\n<p>\"The 40 basis point decline in the yield on the benchmark 10-year Treasury note since late-March suggests that the global grab for yield remains a potent force, despite the Fed's desire to let the economy run hot,\" Steven Ricchiuto, U.S. chief economist at Mizuho Securities, wrote in a note this week.</p>\n<p>\"A stronger currency, increased virus concerns oversea, and the associated demand for long-term Treasury notes and bonds implies reduced inflation expectations and increased risk of importing global deflation,\" he added.</p>\n<p>So-called meme stocks took big hits on Thursday as the sell-off caused investors to flee stocks likeAMCandGameStopthat had been boosted by speculative trading by retail traders chatting on Reddit.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143211463","content_text":"The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Covid-19. The losses came as Japandeclared a state of emergency in Tokyofor the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants.\nThe Dow Jones Industrial Average dropped about 400 points, or 1.1% with losses increasing throughout the overnight session. The S&P 500 lost 1.25%. The Nasdaq 100 Composite fell 1.6%. Both the S&P 500 and Nasdaq Composite closed at records in the prior session because of gains from tech shares.\nThe Labor Department'slatest jobless claims datacame in unexpectedly higher at 373,000, signaling a slowdown in the the labor picture amid the Covid recovery. Economists expected to see 350,000 first-time applicants for unemployment benefits for the week ended July 3, according to Dow Jones.\nPremarket losses were led by companies that would benefit from a rapid economic comeback from the virus. Shares ofCarnivalandRoyal Caribbeaneach dropped more than 3%.American AirlinesandDelta Air Lineseach fell more than 2% in early trading.Boeingfell 2%.FordandNikewere also lower. RetailersLowe'sandHome Depotalso dipped in premarket trading.\nChip stocks also fell on concerns about the pace of the global recovery.Micron,NVIDIA,Qualcomm,IntelandApplied Materialsalso ticked lower in the premarket.\n\"The market has been in one of those 'Goldilocks' stretches when economic growth was accelerating while inflation and interest rates remained low. Increased Covid cases, particularly Delta Variants have caused concerns that the economic acceleration will slow,\" Timothy Lesko of Granite Investment Advisors told CNBC. \"A few weeks ago the porridge was too hot, now it seems it is too cold. With markets at all time highs and some valuations stretched there is little room for economic slowdown in this market.\"\nInvestors rotated into the safety of Treasuries further on Thursday, pushing the yield on the10-year Treasurybelow 1.255% to the lowest since late February. Despite the recovering economy and fast inflation, the 10-year Treasury yield continues to decline. It was at 1.58% to start July and hit a 2021 high of 1.78% in March. Traders remain confused about the exact reasons for the rollover in yields, with many citing concern that the best of the economic recovery may be behind us.\nBank of America,Wells Fargo,Goldman Sachsand other financial shares declined in premarket trading as their profitability outlook dimmed with lower rates.JPMorgan ChaseandPNC Financialwere also lower.\n\"Nothing suggests the near slump in yields is over,\" wrote Christopher Harvey, head of equity strategy at Wells Fargo, in a note Thursday. \"A sharp drop below 1.25% could cause equity PMs to believe that something is wrong or broken. As a result, we see a growing possibility of a 5% selloff in equities before earnings season.\"\nHarvey noted he believes the buying in bonds is more technical in nature and not due to macroeconomic factors.\nSpectatorscould be banned from the Olympic games, according to a report following the state of emergency declaration for Tokyo by Japan.\nMeanwhile the global Covid death toll continued to advance,exceeding 4 million on late Wednesday, as countries including India battle more transmissible variants.\nTheCboe Volatility index, or 'VIX,' surged above the key 20 level Thursday morning, perhaps signaling a period of greater volatility ahead.\n\"The 40 basis point decline in the yield on the benchmark 10-year Treasury note since late-March suggests that the global grab for yield remains a potent force, despite the Fed's desire to let the economy run hot,\" Steven Ricchiuto, U.S. chief economist at Mizuho Securities, wrote in a note this week.\n\"A stronger currency, increased virus concerns oversea, and the associated demand for long-term Treasury notes and bonds implies reduced inflation expectations and increased risk of importing global deflation,\" he added.\nSo-called meme stocks took big hits on Thursday as the sell-off caused investors to flee stocks likeAMCandGameStopthat had been boosted by speculative trading by retail traders chatting on Reddit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156829894,"gmtCreate":1625212638318,"gmtModify":1703738455874,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>this is awesome! Fly soar up more please!!!","listText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>this is awesome! Fly soar up more please!!!","text":"$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$this is awesome! Fly soar up more please!!!","images":[{"img":"https://static.tigerbbs.com/78b0585f0551ccd0cde04f644d3940c5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/156829894","isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":158082154,"gmtCreate":1625113838578,"gmtModify":1703736439566,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158082154","repostId":"1110936297","repostType":2,"repost":{"id":"1110936297","kind":"news","pubTimestamp":1625036047,"share":"https://ttm.financial/m/news/1110936297?lang=&edition=fundamental","pubTime":"2021-06-30 14:54","market":"us","language":"en","title":"Apple: Act Quickly Before The Run To $172","url":"https://stock-news.laohu8.com/highlight/detail?id=1110936297","media":"seekingalpha","summary":"Apple faces many external threats from regulators in the developed world.But I see these as largely priced in, although they remain a threat longer term.Apple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.I have made it no secret that I’m a big fan of Apple. In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a big breakout. In this article, I want to ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Apple faces many external threats from regulators in the developed world.</li>\n <li>But I see these as largely priced in, although they remain a threat longer term.</li>\n <li>Apple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/219c4f41554f7e91be4c02cd87e3f8d6\" tg-width=\"1536\" tg-height=\"1024\"><span>fMing Yeung/Getty Images News</span></p>\n<p>I have made it no secret that I’m a big fan of&nbsp;<b>Apple</b>(AAPL). In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a&nbsp;big breakout. In this article, I want to update readers on the progress of that, as well as addressing some concerns that could be potentially bearish. But the spoiler alert is that I’m still very much in the camp of Apple setting up a breakout, and I think the company’s typical pre-earnings move is likely the catalyst to see that happen.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/37078c4ff01404a43176bb2e2555834d\" tg-width=\"640\" tg-height=\"615\"><span>Source: StockCharts</span></p>\n<p>To start, I’ve annotated the same ascending triangle formation I noted six weeks ago, because it is still very much in play. The stock is very near the top of the triangle today, so what happens when/if it gets to $136/$137 will determine if the breakout is imminent or if we need at least one more test of the rising trend line that forms the bottom of the triangle. Whether that occurs or not doesn’t change my outlook; only the timing of it.</p>\n<p>Ascending triangles measure upside targets on breakouts equal to the top and bottom of the widest part of the triangle. In this case, the top of the triangle is $137 and the bottom of the triangle, which was set in September of last year, was $102. That means that this triangle pattern has a measured price target – after the breakout – of $35 higher ($137 minus $102), and with the breakout point being $137 or so, that implies we canexpect Apple to hit $172, give or take. Now, that won’t happen immediately, of course, but that’s the kind of opportunity at hand here.</p>\n<p>What do you need to look for on a breakout? First, price action needs to decisively clear the breakout level of $137 and close above it. In addition, you want to see rising volume on the breakout – I’ve annotated declining volume in the triangle period, which is normal behavior – and you want to see rising momentum, we’ve got rising momentum today. So I’d expect a breakout to continue that, but these are the things you want to see on a breakout to ensure it has staying power.</p>\n<p>Finally, you’ll notice that I’ve added blue circles on the chart, and those represent the start of the ~4-week period prior to an earnings release. Apple has been<i>very</i>reliable in the past couple of years in terms of rallying into an earnings report, and I have no reason to think that will change. The gains are fairly large in most cases, with about half of them being in the double-digits, so this is a real catalyst for higher prices.</p>\n<p>The important thing to note is that we are about four weeks from the third quarter report, which typically takes place at the end of July. We are also at the top of the ascending triangle, which means that even a small pre-earnings run will likely result in a breakout, and that’s why I think the breakout is very near.</p>\n<p>To be clear, I’m reiterating my prior thesis that an ascending triangle breakout is coming; I just think we have a very clear catalyst now to make it sooner than later. I see the stock rallying into the earnings report, and if history is a guide, Apple will destroy expectations once again. In short, all is going to plan.</p>\n<p>The risk is that if Apple does break out of the triangle and earnings aren’t very good, the pattern could fail. That would negate my $172 price target, and we’d have to reassess. For now, the odds of that look low, and I’m still full steam ahead on the breakout coming pre-earnings.</p>\n<p><b>Why does Apple rally pre-earnings?</b></p>\n<p>To put it succinctly, Apple rallies pre-earnings because no matter how much analysts raise their targets going into the reports, Apple finds a way to beat them.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6233212bc10ea38f20e75d2ed0ab603e\" tg-width=\"640\" tg-height=\"284\"><span>Source:Seeking Alpha</span></p>\n<p>This is three years’ worth of data showing how Apple beats expectations, and by enormous margins in some cases. Apple is one of the largest and most-followed companies that has ever existed. So if any company should have an analyst community that knows how it will perform each quarter, it would be this one. However, its dominance in hardware and services revenue has proven too much for analysts over time to keep up with.</p>\n<p>Keep in mind a risk here is that if Apple does finally miss expectations, I have to imagine the stock will react extremely poorly. Thus, there is certainly risk in owning Apple through the earnings report, as with any other stock. But the company’s history of smashing expectations – particularly in the past year – means the odds of this are fairly low. Still, something to keep in mind from a risk perspective.</p>\n<p>In terms of a catalyst for rallying into the July report, Apple continues to see analysts scramble to keep up with its rising fortunes.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ebf56ca48e2364fd7314f9140bc3ab5c\" tg-width=\"640\" tg-height=\"286\"><span>Source:Seeking Alpha</span></p>\n<p>The sharp upward revisions that began last summer continue unabated, and Apple’s earnings trajectory remains very much intact. I detailed this in my last piece so I’m simply saying that nothing has changed on this front, and that’s a very good thing.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d2bd9aaadd1cc3a29d7b8e787296ab4b\" tg-width=\"454\" tg-height=\"110\"><span>Source:Seeking Alpha</span></p>\n<p>I think you’ll struggle to find a company with a better earnings revision schedule, as the past three months have seen 36 EPS revisions, and<i>100%</i>of them were upward. That shows just how strong Apple’s earnings trajectory is, as analysts scramble to meet Apple’s outstanding performances. I love stocks with earnings revision charts like Apple’s because the bar is always rising, which means that the stock will follow suit.</p>\n<p><b>Not all is well</b></p>\n<p>Apple, to be fair, does face a huge amount of risks that are outside of its control. Many of them cropped up since my last report on Apple and so I want to balance my bullish position on the stock with some sobering reality to ensure readers are well-equipped to make an informed decision about whether or not Apple is right for their portfolio.</p>\n<p>First, the FTC made the headlines a few weeks ago by appointing&nbsp;Lina Khan, an outspoken and noted big tech critic, who feels certain companies have too much control over the behaviors of consumers. This is a noteworthy development because if the FTC wants to go after big tech, Apple is a very logical early target. I don’t see it impacting iPhone or other hardware sales but services revenue? Absolutely. This is a longer-term threat since antitrust rules take time to create, but Apple shareholders need to take this threat seriously.</p>\n<p>The&nbsp;White Houseis apparently on board with this line of thinking, and the&nbsp;House&nbsp;is actually considering legislation that would undertake to reign in the perceived control of big tech companies, including Apple's tendency to pre-install its own apps on Apple devices. Would that stop consumers from just going to the app store and downloading them? No, but it certainly isn't a<i>positive</i>&nbsp;catalyst.</p>\n<p>Apple is facing a similar threat in&nbsp;Germany&nbsp;and other places in the developed world, so it isn’t just a problem at home. Germany is assessing if Apple has “competition violations” to be addressed. So the issue is the same one being faced in the US, and the only two outcomes are neutral (nothing happens), or negative (antitrust action is taken).</p>\n<p>Apple is also still very much beholden to the never-ending trade war between&nbsp;China&nbsp;and the US, as the two countries constantly jockey for position with the highest stakes the world has ever seen in such a scuffle. Apple’s production process is potentially at risk, depending upon how ugly things get, adding some geopolitical risk to the stock's outlook. This goes both ways, and China employs a lot of people and generates a lot of cash from Apple’s production. So I’m not sure it is as one-sided as it seems, but the geopolitical risk is never a good thing, and Apple’s manufacturing needs set it up for such a risk.</p>\n<p><b>Final thoughts</b></p>\n<p>I’ve enumerated a variety of potential issues Apple is facing, and I’ll be clear and say none of these are good things. The best possible outcome is that nothing changes, and the worst is that all come to fruition and Apple faces manufacturing challenges, as well as antitrust actions. These are real threats, but I also think they're already priced in.</p>\n<p>The threat of antitrust legislation or a trade war with China isn’t new by any stretch of the imagination and is not dissimilar to the threats that other tech giants like Amazon (AMZN), Alphabet (GOOG), or Facebook (FB) face every day. This is par for the course if you’re a dominant tech company, and Apple certainly is. I don’t want to ignore these potential negative catalysts, but I don’t want to overreact, either.</p>\n<p>Keep in mind also that Apple continues to move higher over time despite this bad news, which is what winning stocks do. The fact that it is shrugging off these huge potential negative catalysts reinforces the bullish stance I already had on the stock.</p>\n<p>I detailed my bullishness on the company’s revenue generation, margins, buybacks, valuation, and more in the&nbsp;prior piece, and nothing has changed there. So I don’t want to waste your time going through it again. However, my fundamental stance on Apple hasn’t changed in the past six weeks, and if anything, continued upward revisions in EPS estimates have strengthened the bull case.</p>\n<p>The important thing is that shareholders must be aware of external threats, but also that we are seeing Apple get to the end of its very bullish consolidation pattern at the same time that it typically begins a pre-earnings run higher.</p>\n<p>The bottom line is that I think Apple’s breakout is imminent, and that the pattern measures to $172 or so. This won’t happen overnight, but if you were looking to buy Apple, act quickly.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple: Act Quickly Before The Run To $172</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple: Act Quickly Before The Run To $172\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 14:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nApple faces many external threats from regulators in the developed world.\nBut I see these as largely priced in, although they remain a threat longer term.\nApple is on the cusp of what should ...</p>\n\n<a href=\"https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110936297","content_text":"Summary\n\nApple faces many external threats from regulators in the developed world.\nBut I see these as largely priced in, although they remain a threat longer term.\nApple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.\n\nfMing Yeung/Getty Images News\nI have made it no secret that I’m a big fan of Apple(AAPL). In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a big breakout. In this article, I want to update readers on the progress of that, as well as addressing some concerns that could be potentially bearish. But the spoiler alert is that I’m still very much in the camp of Apple setting up a breakout, and I think the company’s typical pre-earnings move is likely the catalyst to see that happen.\nSource: StockCharts\nTo start, I’ve annotated the same ascending triangle formation I noted six weeks ago, because it is still very much in play. The stock is very near the top of the triangle today, so what happens when/if it gets to $136/$137 will determine if the breakout is imminent or if we need at least one more test of the rising trend line that forms the bottom of the triangle. Whether that occurs or not doesn’t change my outlook; only the timing of it.\nAscending triangles measure upside targets on breakouts equal to the top and bottom of the widest part of the triangle. In this case, the top of the triangle is $137 and the bottom of the triangle, which was set in September of last year, was $102. That means that this triangle pattern has a measured price target – after the breakout – of $35 higher ($137 minus $102), and with the breakout point being $137 or so, that implies we canexpect Apple to hit $172, give or take. Now, that won’t happen immediately, of course, but that’s the kind of opportunity at hand here.\nWhat do you need to look for on a breakout? First, price action needs to decisively clear the breakout level of $137 and close above it. In addition, you want to see rising volume on the breakout – I’ve annotated declining volume in the triangle period, which is normal behavior – and you want to see rising momentum, we’ve got rising momentum today. So I’d expect a breakout to continue that, but these are the things you want to see on a breakout to ensure it has staying power.\nFinally, you’ll notice that I’ve added blue circles on the chart, and those represent the start of the ~4-week period prior to an earnings release. Apple has beenveryreliable in the past couple of years in terms of rallying into an earnings report, and I have no reason to think that will change. The gains are fairly large in most cases, with about half of them being in the double-digits, so this is a real catalyst for higher prices.\nThe important thing to note is that we are about four weeks from the third quarter report, which typically takes place at the end of July. We are also at the top of the ascending triangle, which means that even a small pre-earnings run will likely result in a breakout, and that’s why I think the breakout is very near.\nTo be clear, I’m reiterating my prior thesis that an ascending triangle breakout is coming; I just think we have a very clear catalyst now to make it sooner than later. I see the stock rallying into the earnings report, and if history is a guide, Apple will destroy expectations once again. In short, all is going to plan.\nThe risk is that if Apple does break out of the triangle and earnings aren’t very good, the pattern could fail. That would negate my $172 price target, and we’d have to reassess. For now, the odds of that look low, and I’m still full steam ahead on the breakout coming pre-earnings.\nWhy does Apple rally pre-earnings?\nTo put it succinctly, Apple rallies pre-earnings because no matter how much analysts raise their targets going into the reports, Apple finds a way to beat them.\nSource:Seeking Alpha\nThis is three years’ worth of data showing how Apple beats expectations, and by enormous margins in some cases. Apple is one of the largest and most-followed companies that has ever existed. So if any company should have an analyst community that knows how it will perform each quarter, it would be this one. However, its dominance in hardware and services revenue has proven too much for analysts over time to keep up with.\nKeep in mind a risk here is that if Apple does finally miss expectations, I have to imagine the stock will react extremely poorly. Thus, there is certainly risk in owning Apple through the earnings report, as with any other stock. But the company’s history of smashing expectations – particularly in the past year – means the odds of this are fairly low. Still, something to keep in mind from a risk perspective.\nIn terms of a catalyst for rallying into the July report, Apple continues to see analysts scramble to keep up with its rising fortunes.\nSource:Seeking Alpha\nThe sharp upward revisions that began last summer continue unabated, and Apple’s earnings trajectory remains very much intact. I detailed this in my last piece so I’m simply saying that nothing has changed on this front, and that’s a very good thing.\nSource:Seeking Alpha\nI think you’ll struggle to find a company with a better earnings revision schedule, as the past three months have seen 36 EPS revisions, and100%of them were upward. That shows just how strong Apple’s earnings trajectory is, as analysts scramble to meet Apple’s outstanding performances. I love stocks with earnings revision charts like Apple’s because the bar is always rising, which means that the stock will follow suit.\nNot all is well\nApple, to be fair, does face a huge amount of risks that are outside of its control. Many of them cropped up since my last report on Apple and so I want to balance my bullish position on the stock with some sobering reality to ensure readers are well-equipped to make an informed decision about whether or not Apple is right for their portfolio.\nFirst, the FTC made the headlines a few weeks ago by appointing Lina Khan, an outspoken and noted big tech critic, who feels certain companies have too much control over the behaviors of consumers. This is a noteworthy development because if the FTC wants to go after big tech, Apple is a very logical early target. I don’t see it impacting iPhone or other hardware sales but services revenue? Absolutely. This is a longer-term threat since antitrust rules take time to create, but Apple shareholders need to take this threat seriously.\nThe White Houseis apparently on board with this line of thinking, and the House is actually considering legislation that would undertake to reign in the perceived control of big tech companies, including Apple's tendency to pre-install its own apps on Apple devices. Would that stop consumers from just going to the app store and downloading them? No, but it certainly isn't apositive catalyst.\nApple is facing a similar threat in Germany and other places in the developed world, so it isn’t just a problem at home. Germany is assessing if Apple has “competition violations” to be addressed. So the issue is the same one being faced in the US, and the only two outcomes are neutral (nothing happens), or negative (antitrust action is taken).\nApple is also still very much beholden to the never-ending trade war between China and the US, as the two countries constantly jockey for position with the highest stakes the world has ever seen in such a scuffle. Apple’s production process is potentially at risk, depending upon how ugly things get, adding some geopolitical risk to the stock's outlook. This goes both ways, and China employs a lot of people and generates a lot of cash from Apple’s production. So I’m not sure it is as one-sided as it seems, but the geopolitical risk is never a good thing, and Apple’s manufacturing needs set it up for such a risk.\nFinal thoughts\nI’ve enumerated a variety of potential issues Apple is facing, and I’ll be clear and say none of these are good things. The best possible outcome is that nothing changes, and the worst is that all come to fruition and Apple faces manufacturing challenges, as well as antitrust actions. These are real threats, but I also think they're already priced in.\nThe threat of antitrust legislation or a trade war with China isn’t new by any stretch of the imagination and is not dissimilar to the threats that other tech giants like Amazon (AMZN), Alphabet (GOOG), or Facebook (FB) face every day. This is par for the course if you’re a dominant tech company, and Apple certainly is. I don’t want to ignore these potential negative catalysts, but I don’t want to overreact, either.\nKeep in mind also that Apple continues to move higher over time despite this bad news, which is what winning stocks do. The fact that it is shrugging off these huge potential negative catalysts reinforces the bullish stance I already had on the stock.\nI detailed my bullishness on the company’s revenue generation, margins, buybacks, valuation, and more in the prior piece, and nothing has changed there. So I don’t want to waste your time going through it again. However, my fundamental stance on Apple hasn’t changed in the past six weeks, and if anything, continued upward revisions in EPS estimates have strengthened the bull case.\nThe important thing is that shareholders must be aware of external threats, but also that we are seeing Apple get to the end of its very bullish consolidation pattern at the same time that it typically begins a pre-earnings run higher.\nThe bottom line is that I think Apple’s breakout is imminent, and that the pattern measures to $172 or so. This won’t happen overnight, but if you were looking to buy Apple, act quickly.","news_type":1},"isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897013387,"gmtCreate":1628862601349,"gmtModify":1676529878607,"author":{"id":"4087475573507020","authorId":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020","authorIdStr":"4087475573507020"},"themes":[],"htmlText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","listText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","text":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897013387","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://ttm.financial/m/news/1141206470?lang=&edition=fundamental","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}